Measles virus: Questions

History.

• Vaccination history — number and dates of measles-containing-vaccine doses; check the Road-to-Health booklet. A dose within ~6 weeks can cause a false-positive IgM.
• Recent contacts — confirmed or suspected measles in household, school, daycare, or healthcare setting.
• Travel to or from a known outbreak area in the preceding 7–21 days.
• Illness timeline — fever course, rash onset and spread, the three C’s (cough, coryza, conjunctivitis), and look specifically for Koplik’s spots.
• Risk and red flags — HIV status, other immunosuppression, malnutrition / vitamin-A deficiency, dehydration, respiratory distress, altered consciousness, eye symptoms.
• Susceptible household contacts — infants <12 months, pregnant women, immunocompromised members: these are the PEP candidates.

Samples — and notify NICD immediately (measles is a Category 1 NMC):

• Serum (≥1 mL) for measles IgM (paired IgG if clinically indicated). IgM may be undetectable for the first 4–5 days after rash; if negative early with high clinical suspicion, repeat between days 4 and 28.
• Throat / NP swab (or oral fluid) in viral transport medium for RT-PCR — ideally within 4 days of rash, useful up to 7.
• Urine (~30 mL, clean-catch) for RT-PCR — slightly longer detection window.
• CSF only if encephalitis is suspected.

RT-PCR-positive material also supports genotyping at the NICD reference laboratory for outbreak source attribution.

SA case definition

The NICD aligns with the WHO clinical case definition, with four tiers under the Notifiable Medical Condition (NMC) framework:

• Suspected case — fever + generalised maculopapular (non-vesicular) rash + at least one of cough, coryza, or conjunctivitis. Or any case a clinician considers compatible with measles.
• Laboratory-confirmed — a suspected case with positive measles IgM, measles RNA by RT-PCR, or a 4-fold rise in measles IgG between paired sera; and no measles-containing vaccine within ~6 weeks (which can cause false-positive IgM).
• Epidemiologically linked — a suspected case with documented exposure to a lab-confirmed case (acceptable in an established outbreak).
• Discarded — investigated and lab-negative.

Context of use

Measles is a Category 1 NMC — suspected cases must be reported to NICD immediately (within 24 hours). The definition drives:

• the public-health response — contact tracing, PEP for susceptible contacts, exclusion of cases and unvaccinated contacts;
• elimination surveillance — SA, as part of the WHO African Region, is measured against indicators including the discarded non-measles-case rate and the proportion of suspected cases with adequate specimens;
• early outbreak detection — a single lab-confirmed case in a previously elimination-status area triggers an outbreak response.

Role of the laboratory

In a suspected case — confirm or exclude with measles IgM serology (routine) and RT-PCR on respiratory/urine/oral-fluid specimens (more sensitive in early disease and in the immunocompromised). Test relevant differentials, particularly rubella IgM (also reportable, same elimination programme), and parvovirus B19, dengue or chikungunya as clinical features dictate. Notify NICD on any positive result.

In a confirmed case — genotype at the NICD reference laboratory (450-nt N-gene C-terminal region, sometimes the H gene) to assign one of the 8 clades / 24 genotypes. Genotyping supports source attribution (imported vs endemic), transmission-chain mapping, vaccine-strain identification (when a vaccinee presents IgM-positive), and submission to the WHO MeaNS database — required for elimination certification (continuous interruption of endemic genotype for ≥12 months).

The laboratory is therefore both a clinical service (confirming the case in front of the registrar) and a public-health instrument (elimination surveillance and outbreak attribution).

Measles virus (MeV) is a non-segmented, negative-sense, single-stranded RNA virus (Baltimore Group V), family Paramyxoviridae, genus Morbillivirus. Only one serotype exists, infection confers lifelong immunity, and the WHO recognises 8 clades (A–H) and 24 genotypes — used for molecular outbreak surveillance, not antigenic classification.

Virion. Enveloped, spherical, helical nucleocapsid, ~150 nm. The host-derived lipid envelope carries two transmembrane glycoproteins (H and F), lined internally by the matrix (M) protein.

Genome. Linear ssRNA, ~16,000 nucleotides, encoding six structural proteins (N, P, L, M, F, H) and two non-structural proteins from the P gene (C and V) that antagonise host interferon responses.

H (haemagglutinin) is the receptor-binding glycoprotein and the dominant target of neutralising antibodies. It binds three receptors:

• CD150 / SLAM — on activated immune cells; the primary wild-type receptor, explaining initial lymphoid tropism.
• Nectin-4 — on epithelial cells; drives respiratory spread and airway shedding.
• CD46 — used preferentially by attenuated vaccine strains; wild-type virus uses it poorly.

F (fusion) mediates envelope–membrane fusion. Synthesised as inactive F₀ and cleaved by furin into active F₁/F₂; fusion requires coexpression of H, whose receptor binding triggers the conformational change exposing the F₁ fusion peptide.

Despite the variability typical of an RNA virus, conserved neutralising epitopes on H have kept MeV monotypic through centuries of immune pressure.

The two parallel SA vaccines

The two are pharmacologically similar live-attenuated products with a shared adverse-event profile.

Contraindications

The clinically important contraindications (both vaccines):

• Pregnancy — and planning pregnancy within 3 months; pregnancy should be avoided for 1 month after vaccination. Live attenuated vaccines.
• Severe immunosuppression — congenital immunodeficiency, haematological malignancy on treatment, post-transplant immunosuppression, high-dose corticosteroids (≥2 mg/kg/day or ≥20 mg/day prednisone-equivalent for ≥2 weeks) or other potent immunosuppressives, or HIV with low CD4 (<15% if ≤5 yr; <15% and count <200/µL if >5 yr).
• Severe allergic reaction to a previous dose, or known anaphylaxis to vaccine components — notably neomycin or gelatin.

Precautions and risk groups

• Defer for systemic illness with temperature >38.5 °C; minor illness is not a contraindication.
• HIV-infected children — safe unless severely immunocompromised (above thresholds); no increased risk of serious adverse events.
• Neurological disorders / epilepsy / family history of febrile seizures — benefits outweigh risks, but counsel on the known increased risk of febrile seizures after vaccination.
• Egg allergy — safe; residual ovalbumin is minimal. (The older “egg allergy is a contraindication” teaching is out of date.)
• Health-care workers — especially important to vaccinate, given documented outbreaks in healthcare settings.
• MMRV is contraindicated in HIV regardless of CD4 — use MMR.
• Recent immunoglobulin or blood products — defer 3–11 months depending on product (passive antibody neutralises the live vaccine).
• Personal history of ITP — small risk of recurrence; weigh against measles risk.

Adverse events

Mostly mild: injection-site reactions, low-grade fever, transient rash. Less common: febrile seizures (especially after the first dose), arthralgia, transient thrombocytopaenia. Rare: anaphylaxis, encephalitis.

Post-exposure prophylaxis

Per the NICD framework (Prevention of secondary cases, 2022). PEP goes to any contact without documented immunity who was exposed during the index case’s infectious period (4 days before to 4 days after rash).

(i) Immunocompetent child. Measles-containing vaccine within 72 hours of exposure — MR (Cipla) in the public sector, MMR in the private. Still worth giving after 72 hours (safe in someone already incubating; boosts the already-immune). For infants 6–8 months, the PEP dose does not replace the routine schedule. Infants <6 months are too young for live vaccine and need NHIG if the mother is non-immune. Effectiveness (NEJM 2025 meta-analysis): 83–100%.

(ii) Immunocompromised contact (or vaccine-contraindicated). Normal human immunoglobulin (NHIG) 0.5 mL/kg IM (max 15 mL) within 6 days. Candidates: severe primary immunodeficiency, haematological malignancy on chemotherapy, HSCT/SOT recipients on immunosuppression, HIV with CD4 below thresholds above, infants <6 months whose mothers are non-immune, pregnant women without evidence of immunity. Caveat: the measles-neutralising antibody content of contemporary NHIG has declined (donors are increasingly vaccine- rather than naturally-immune) — efficacy is uncertain and the recommended dose is under review. Effectiveness: 76–100%, with greater short-term protection than vaccine but greater cost and limited LMIC availability. For HIV-infected contacts, the NICD recommends vaccine within 72 h if CD4 is adequate, NHIG otherwise.

In all cases, notify the NICD — measles is a Category 1 NMC.

Incubation. ~10–14 days from exposure to clinical illness.

Prodrome (2–4 days). Fever (often >38.5 °C) with the classical “three C’s” — cough, coryza, conjunctivitis. Infectious from ~4 days before to ~4 days after rash, so most onward transmission happens before the diagnosis is recognisable.

Koplik’s spots — pathognomonic. Small (~1 mm) bluish-white papules on an erythematous base on the buccal mucosa opposite the lower molars, appearing 1–2 days before the exanthem and lasting 1–2 days after rash onset. Easily missed unless actively looked for, but diagnostic when seen.

Exanthem. Erythematous maculopapular rash beginning behind the ears and on the face, spreading cephalo-caudally over 3–4 days to trunk, limbs, palms and soles. May become confluent and darken; fades in the same order it appeared, sometimes with fine desquamation.

Acute complications

• Otitis media — commonest.
• Pneumonia — secondary bacterial (the leading cause of measles death) or giant-cell pneumonia in immunocompetent children.
• Laryngotracheobronchitis (croup).
• Diarrhoea with dehydration — especially in malnourished children.
• Keratoconjunctivitis — corneal scarring and blindness in vitamin-A-deficient settings; a major cause of paediatric blindness in low-income countries.
• Myocarditis — rare.

Neurological complications

ADEM is post-infectious and immune-mediated; MIBE and SSPE reflect persistent CNS infection with defective virus.

Late effects

Prolonged immune suppression — “immune amnesia” — may increase mortality from unrelated infections for months after recovery. Largely abrogated by vaccination; one of the strongest non-rash arguments for sustaining high coverage.

Primary vs secondary vaccine failure

Primary vaccine failure — failure to seroconvert after vaccination. About 10–15% of infants given the first dose at 9 months fail to seroconvert (lower with later dosing). Main contributors:

• Maternal-antibody interference — passively-acquired IgG neutralises live vaccine virus in young infants (the reason elimination-status countries delay the first dose to 12–18 months).
• Younger age at vaccination — lower immunogenicity.
• Host immune compromise at the time of vaccination (HIV with low CD4, congenital immunodeficiency, immunosuppressive therapy).
• Cold-chain failure — measles vaccine is live and heat-labile.
• Moderate-to-severe acute illness at vaccination.

Secondary vaccine failure — waning immunity in someone who did initially respond. Vaccine-induced antibody levels are lower than those from natural infection, and without boosting from circulating wild-type virus (as elimination is approached) can fall below the protective threshold. Breakthrough infections are usually milder and shorter (“modified measles”) but the patient can still transmit.

SA schedule — public and private sectors

Public sector — EPI

Since 2023/2024 the EPI uses the MR (measles-rubella) vaccine from Cipla. Two routine doses:

• Dose 1: 6 months — SA is one of only two countries (the other is China, at 8 months) giving the first dose this early, to protect infants once maternal antibodies wane. The MR-Cipla PIL states a minimum age of 9 months, so the 6-month dose is off-label per the regulatory PIL, administered under NDoH/EPI policy aligned with WHO recommendations for high-transmission settings.
• Dose 2: 12 months (minimum 4-week inter-dose interval per WHO).

Private sector

MMR or MMRV (with varicella) is used, typically at 12 months and 4–6 years. Catch-up applies to older children and adults without documented immunity.

Supplementary doses (both sectors)

Additional doses are given for outbreak response (SIAs) and post-exposure prophylaxis within 72 hours. A PEP dose given before the routine first dose does not replace it — the routine schedule must still be completed.

Four pillars — specimens, serology, RT-PCR, and (in confirmed cases) genotyping — matched to the clinical phase, immune status, and public-health question.

Specimens

In early disease, submit more than one specimen type — RT-PCR sensitivity is highest on respiratory specimens and urine before IgM is reliably detectable.

Serology

• Measles IgM by EIA — detectable ~4–5 days after rash, peaks 1–3 weeks, undetectable within 4–8 weeks. A positive IgM in a clinically compatible case confirms acute infection.
• 4-fold IgG rise between paired sera (2–4 weeks apart) — also confirms acute infection.
• Low-avidity IgG indicates recent primary response.
• Single high IgG, normal avidity = prior infection or vaccination, not acute disease.

Caveats. Recent measles-containing vaccine (within ~6 weeks) can cause false-positive IgM. In a secondary immune response (breakthrough infection in a vaccinated person) IgM may be positive at a lower IgM:IgG ratio — avidity testing distinguishes. In immunocompromised patients, IgM may be negative altogether and RT-PCR is essential.

RT-PCR

Detects MeV RNA in respiratory/urine specimens using primers targeting conserved regions of N, M or F genes. Especially valuable in:

1. Early disease — before IgM is reliably detectable.
2. Immunocompromised patients — who may fail to seroconvert.
3. CNS disease — useful in MIBE.
4. Outbreak investigation — rapid confirmation and feeds genotyping.

Genotyping

Sequencing the 450-nucleotide C-terminal region of the N gene (and sometimes the H gene) assigns one of the WHO-recognised 8 clades / 24 genotypes. The NICD reference laboratory submits sequences to the WHO MeaNS database. Genotyping enables source attribution (imported vs endemic), transmission-chain mapping, vaccine-strain identification, and documentation of elimination (continuous interruption of an endemic genotype for ≥12 months — an SA/WHO African Region target).

Differentials

If measles is excluded, test rubella IgM (also reportable), and as features dictate parvovirus B19, dengue or chikungunya (travel), and HHV-6 in young children.

There is no approved antiviral for measles. Management rests on supportive care, vitamin A, early treatment of complications, and isolation.

Supportive care

• Hydration — oral where possible; IV fluids for moderate-to-severe dehydration. Measles causes both reduced intake (mouth ulcers, malaise) and increased losses (diarrhoea, fever).
• Antipyretics — paracetamol. Avoid aspirin (Reye’s syndrome).
• Nutritional support — measles is catabolic; malnutrition worsens prognosis. Refer for nutritional rehabilitation if signs of acute malnutrition.
• Respiratory support — oxygen and ventilation as needed for pneumonia.
• Eye care — gentle cleansing of discharge; topical lubrication; vitamin A is the key intervention against corneal scarring.

Vitamin A

WHO recommends vitamin A for all children with acute measles since 1993, regardless of timing of previous doses or suspected deficiency. RCTs in LMICs showed a 34–50% reduction in mortality in children 1–5 years.

A third dose 2–4 weeks later is given for clinical eye signs of vitamin A deficiency or severe malnutrition.

Use only WHO-recommended doses — unsupervised high-dose vitamin A is toxic (intakes >1500 IU/kg/day in children have caused toxicity; the NEJM 2025 review flags toxicity cases in recent US outbreaks).

Ribavirin

Not approved and not routinely recommended. Anecdotal use in severe disease in the immunocompromised, MIBE, or severe pneumonia; no RCT evidence. Specialist input only.

Complications-directed treatment

• Bacterial pneumonia (commonest cause of measles death) — empirical antibiotics per local guidance; not given prophylactically.
• Otitis media — amoxicillin first-line.
• Croup — supportive ± nebulised adrenaline ± corticosteroid if severe.
• Diarrhoea — oral rehydration; zinc per WHO paediatric protocols.
• Acute encephalitis / ADEM — supportive ICU care, anticonvulsants; corticosteroids sometimes used in ADEM (observational evidence).
• MIBE and SSPE — no proven treatment; supportive/palliative.

Isolation and notification

• Airborne precautions in hospital (negative-pressure room where available; N95/FFP2 for staff). NICD pre-hospital guidance: standard
  • contact + droplet precautions.
• Isolate / exclude from school, work and healthcare facilities for 4 days after rash onset.
• Notify NICD immediately — measles is a Category 1 NMC.

Post-recovery (emerging)

The NEJM 2025 review highlights that most post-measles pneumonia is pneumococcal and raises the possibility of a strategically-timed pneumococcal conjugate booster after recovery — research direction, not yet a standard recommendation.

Epidemiology

SSPE is a rare, delayed, invariably fatal complication of measles caused by persistent CNS infection with defective measles virus.

• Incidence: historically quoted as ~1 in 10,000 measles cases; NEJM 2025 cites 7–11 per 100,000 cases, and recent surveillance suggests it may be more common than previously estimated (Wendorf et al., 2017).
• Latent period: typically 6–10 years after primary infection (range 1 to >30 years).
• Major risk factor: measles infection at <2 years of age — the immature immune response permits establishment of persistent CNS infection.
• Host: previously immunocompetent individuals — contrast with MIBE, which occurs in the immunocompromised.
• Outcome: progressive, with periodic remissions; death within 1–3 years of onset in most patients.
• Public-health pattern: SSPE incidence falls as measles is suppressed by vaccination, and rises 5–10 years after major measles outbreaks — vaccination is the only meaningful prevention.

Clinical course

Insidious onset over months, progressing through four stages:

1. Subtle behavioural changes — personality change, declining school performance.
2. Motor signs — awkwardness, stumbling, then myoclonic jerks and seizures.
3. Progressive cortical decline — ataxia, dementia, extrapyramidal signs (choreoathetosis, dystonic posturing).
4. Late — visual loss (chorioretinitis, optic atrophy, cortical blindness), spasticity, coma.

Diagnosis — the classic triad

1. Clinical — gradual, progressive behavioural change, myoclonus, dementia, visual disturbance, and pyramidal/extrapyramidal signs.
2. EEG — periodic high-amplitude slow-wave complexes (Radermecker complexes) at 4–20 second intervals, typically synchronised with myoclonus.
3. CSF measles-specific antibody — exceptionally high MeV-specific IgG, with oligoclonal bands on electrophoresis, and a markedly elevated CSF:serum MeV antibody ratio indicating intrathecal synthesis.

Supporting investigations: MRI shows progressive white-matter abnormalities and later cortical atrophy. Brain biopsy (rarely needed) shows diffuse encephalitis with intranuclear and intracytoplasmic inclusion bodies. RT-PCR may detect MeV RNA but is unreliable.

Pathology. Diffuse encephalitis of grey and white matter with perivascular cuffing, lymphocytic infiltration, microglial proliferation, and patchy demyelination. Inclusion bodies contain MeV ribonucleocapsids; infectious virus cannot be recovered — the defective MeV in SSPE brains has mutations throughout the genome, especially in the M, H and F genes, preventing virion assembly.

Differential

Other progressive encephalopathies: prion disease (CJD), HIV encephalopathy, autoimmune encephalitis, leukodystrophies.

Entry. Measles virus (MeV) enters via the respiratory mucosa or conjunctivae. The earliest targets are alveolar macrophages and dendritic cells via SLAM (CD150), which carry virus to draining lymph nodes.

Primary viraemia (days 2–4). Infected monocytes disseminate MeV through the reticulo-endothelial system — tonsils, spleen, thymus, lymph nodes, Peyer’s patches — producing the characteristic multinucleated giant (Warthin–Finkeldey) cells and Cowdry type A intranuclear inclusions.

Secondary viraemia (days 5–7). Virus spreads to epithelial sites via Nectin-4 — skin (exanthem), conjunctivae, oropharynx (Koplik’s spots), respiratory and GI tracts, kidneys and CNS. The prodrome and exanthem reflect immune-mediated injury at these sites.

Immunological effects.

• Profound transient immunosuppression — lymphopenia, depletion of memory T and B cells, impaired cell-mediated immunity for weeks to months. This is why most measles deaths are due to secondary infections (bacterial pneumonia in particular), not the virus itself.
• A concurrent robust MeV-specific response confers lifelong immunity.
• In severe immunocompromise the rash may be absent, shedding is prolonged, and MeV can persist in the CNS to cause MIBE (months later) or SSPE (years later).

Measles probably evolved from rinderpest, a virus of cattle, once human populations grew large enough to sustain transmission without an animal reservoir, the birth of a crowd disease. Smallpox, by contrast, is most closely related to camelpox.

Most likely diagnosis

Measles. The combination of a generalised (typically maculopapular) rash with the three C’s — cough, coryza (runny nose), and conjunctivitis (red eyes) — is the classical clinical syndrome. Also look for Koplik’s spots on the buccal mucosa, which are pathognomonic if seen.

Appropriate diagnostic tests

• Serum measles IgM — the routine surveillance test; positive in a clinically compatible case confirms acute infection.
• RT-PCR on a throat/NP swab (or oral fluid) and/or urine — more sensitive than IgM in the first 4–5 days of rash, and useful for genotyping in outbreak investigation.
• Consider rubella IgM as a differential (similarly reportable).

Public-health actions

Notify the NICD immediately — measles is a Category 1 Notifiable Medical Condition. Exclude the child from school and public settings for 4 days after rash onset, and identify household and class contacts for post-exposure prophylaxis (see the PEP answer).

For the full clinician workup (history points and specimen handling), see the suspected-measles workup answer.

Three common viral causes

• Measles (rubeola)
• Rubella (German measles)
• Parvovirus B19 (fifth disease / “slapped-cheek” syndrome)

(Others to consider in this age group: human herpesvirus 6 — though usually under 2 years — and enterovirus.)

Distinguishing features — measles vs rubella

Laboratory investigations (with resource stewardship + IPC)

• Targeted testing, not a shotgun panel:
  • Measles IgM (serum) — first-line if features are classical;
  • Rubella IgM (serum) — added as the principal differential (same elimination programme);
  • RT-PCR on throat/NP swab, oral fluid or urine — adds sensitivity in early disease and enables genotyping.
• Add parvovirus B19 IgM if rash is “slapped-cheek” / lacy reticular, or if there are aplastic features.
• Take history-driven differentials only — dengue/chikungunya for travel, HHV-6 in toddlers, drug history.
• Infection control: isolate suspected measles immediately under airborne precautions (negative-pressure room, N95/FFP2 for staff). Rubella requires droplet precautions. Notify NICD immediately — measles and rubella are Category 1 NMCs.

Eradication target

Measles is targeted for global eradication. Two features making this feasible:

1. No animal reservoir — humans are the sole natural host, so interrupting human-to-human transmission terminates the virus.
2. A single antigenic type with lifelong immunity after infection or full vaccination — there is no antigenic drift, and a highly immunogenic live vaccine exists.

(See the eradication-feasibility answer for the deeper discussion and current barriers.)

Replication of measles virus (MeV) is the canonical paramyxovirus cycle — entirely cytoplasmic, with no DNA intermediate and no nuclear phase.

1. Attachment. The H glycoprotein binds a host receptor: SLAM (CD150) on activated immune cells (primary wild-type receptor), Nectin-4 on epithelial cells (secondary spread and airway shedding), or CD46 (preferentially used by attenuated vaccine strains).
2. Fusion and entry. Receptor engagement triggers a conformational change in F, exposing the fusion peptide. F fuses the viral envelope with the host plasma membrane (pH-independent), releasing the helical nucleocapsid into the cytoplasm.
3. Transcription. The viral RNA-dependent RNA polymerase (L, with P as cofactor) transcribes capped, polyadenylated monocistronic mRNAs from the negative-sense ssRNA genome, working sequentially N → P → M → F → H → L. Periodic polymerase detachment between genes produces a 3′→5′ mRNA abundance gradient (N most abundant, L least).
4. Translation. Structural proteins (N, P, M, F, H, L) plus two non-structural proteins from the P gene (C and V) — the latter antagonise host interferon responses.
5. Switch to genome replication. As cytoplasmic N accumulates, it encapsidates nascent RNA, suppressing transcription termination signals — the polymerase reads through gene boundaries to produce full-length positive-sense antigenome, then full-length negative-sense progeny genomes, each coated by N.
6. Glycoprotein processing. H and F are translated, glycosylated in the ER and processed in the Golgi. F is cleaved by host furin into the active disulfide-linked F₁/F₂ form before reaching the plasma membrane.
7. Assembly. The matrix protein M binds progeny nucleocapsids on the inner face of the plasma membrane and links them to the cytoplasmic tails of H and F. M also excludes host membrane proteins from patches of the bilayer destined for budding.
8. Budding. Virions bud from the plasma membrane; actin filaments help transport nucleocapsids to the budding site. Because F is cleaved before assembly, virions are immediately infectious — no post-budding maturation step is required.

Two practical consequences of this cycle: multinucleated giant cells (syncytia) form in infected tissue because surface H and F drive cell-to-cell fusion with neighbouring cells; and the cycle is the basis for both vaccine attenuation (passaged strains with altered receptor usage and reduced epithelial replication) and for the defective virus of SSPE (mutations in M, H, and F that abolish virion assembly while permitting cell-to-cell spread).

Measles meets the Dahlem Conference (1997) preconditions for eradication of an infectious disease — and yet remains the only major vaccine-preventable disease that has eluded elimination over decades of effort.

Why eradication is biologically feasible

• No animal reservoir — humans are the sole natural host. There is no zoonotic source to repopulate the virus once human transmission is interrupted (cf. yellow fever).
• Single serotype — MeV is monotypic, with no antigenic drift. Vaccines made in the 1960s still neutralise contemporary wild-type strains.
• Lifelong immunity — both natural infection and complete vaccination confer durable protection.
• Highly immunogenic vaccine — a single dose seroconverts ~85% of infants at 9 months and ~95% if given later; two doses approach 100% protection.
• Clinically recognisable disease — surveillance can detect cases.
• Sensitive and specific laboratory tools — IgM serology, RT-PCR and genotyping enable confirmation and source attribution (WHO Measles Nucleotide Surveillance, MeaNS).

Why eradication is operationally hard

• R₀ of 12–18 — measles is one of the most contagious infections known. The herd-immunity threshold is ≥95% two-dose coverage, which most countries struggle to attain or sustain.
• Vaccine hesitancy — the most rapidly-growing barrier; the NEJM 2025 review highlights it as the dominant current threat.
• COVID-19 disruption — global immunisation services were set back, with measles vaccination coverage falling sharply in 2020–2022 and outbreaks resurging from 2023 onward.
• Funding and political headwinds — recent reductions in WHO and Gavi funding (the NEJM 2025 specifically notes the US withdrawal from global public-health programs) are projected to worsen LMIC coverage and global control.
• The young-infant immunity gap — infants <6 months are still protected by maternal antibody but become susceptible before reliable vaccine response is achievable, leaving a window of risk that current vaccines cannot close. New vaccine technologies (e.g. microneedle patches, formulations effective from earlier ages) are research priorities.
• Conflict and humanitarian crises — disrupt routine immunisation and the cold chain, and concentrate susceptible populations.

Where the programme is

WHO regions have set elimination targets in sequence. The Americas achieved measles elimination in 2016 (later re-established transmission); the European, Western Pacific and African Regions are working toward elimination. Globally >395,000 laboratory- confirmed measles cases were reported in 2024 (NEJM 2025), with the true number probably several-fold higher.

Eradication remains technically achievable; the obstacles are operational, political and social rather than biological.

There is no association. The MMR–autism question is one of the most thoroughly investigated in modern epidemiology, and the evidence is unequivocal: MMR vaccination does not cause autism.

Origin of the claim

The supposed link came from a 1998 case series of 12 children by Andrew Wakefield in The Lancet, proposing a link between MMR, inflammatory bowel disease and autism. The paper was:

• Methodologically poor — small, selected, uncontrolled.
• Fraudulent — Wakefield manipulated data and concealed financial conflicts of interest (he was being paid by lawyers preparing to sue vaccine manufacturers).
• Retracted by The Lancet in 2010; Wakefield was struck off the UK medical register the same year.

The evidence

Multiple large cohort and case–control studies have excluded any link:

• Madsen et al., N Engl J Med 2002 — Danish cohort of >500,000 children; no association.
• Hviid et al., Ann Intern Med 2019 — Danish cohort of >650,000 children, including high-risk subgroups (autism in family, multiple vaccinations); no association even on subgroup analysis.
• Consistent null results from multiple other countries and study designs. See DeStefano & Shimabukuro, Annu Rev Virol 2019 for the canonical review.

No biologically plausible mechanism has been identified. The temporal coincidence of MMR (given at 12–15 months in most schedules) and the typical age of autism diagnosis is what generated the original suspicion; large studies controlling for age have shown autism rates are no higher in vaccinated than in unvaccinated children.

Public-health consequences

Despite conclusive disproof, the Wakefield paper has fuelled persistent vaccine hesitancy. Declines in MMR coverage have driven measles resurgence — most prominently in the UK in the 2000s, in US outbreaks (notably 2019 and 2024–25), and in the 2019 Samoa outbreak which killed ~80 children, mostly under five. The NEJM 2025 review identifies vaccine hesitancy as the dominant current barrier to measles eradication.

Clinical implication

Counsel parents firmly and clearly: MMR does not cause autism. The original claim was fraudulent and has been comprehensively disproven. The greater risk by far is not vaccinating — measles itself causes encephalitis, pneumonia, prolonged immunosuppression, and, in 7–11 per 100,000 cases, the invariably fatal SSPE.

Three clinical patterns of measles, defined by the host’s immune state and (historically) prior vaccine type.

Typical (classic) measles

The well-recognised syndrome. After a 10–14-day incubation:

• Prodrome (2–4 days) — fever (often >38.5 °C) with the three C’s (cough, coryza, conjunctivitis).
• Koplik’s spots on the buccal mucosa — pathognomonic; appear 1–2 days before the rash.
• Exanthem — erythematous maculopapular rash, begins behind the ears and on the face/hairline, spreads cephalo-caudally over 3–4 days to trunk, limbs, palms and soles; may become confluent and darken, then fades with fine desquamation.
• Infectious 4 days before to 4 days after rash onset.

(See the clinical-features answer for the complete picture and complications.)

Atypical measles syndrome

Originally described in the 1960s in children who had received the killed (inactivated) measles vaccine in use 1963–1967. On subsequent exposure to wild-type measles, these children developed an unusual, often severe illness:

• High fever, headache, abdominal pain.
• Marked respiratory disease — interstitial pneumonia with pleural effusion.
• Rash starts on the extremities (palms and soles) and spreads centripetally — opposite to the classic cephalo-caudal pattern.
• Rash may be vesicular, petechial or purpuric.
• Markedly raised antibody titres — pathophysiology is a hypersensitivity reaction to wild-type virus on a background of incomplete vaccine-induced immunity (the killed vaccine generated antibody to H but not F, so cell-to-cell spread of wild-type virus was not neutralised).

Now rare (the killed vaccine was withdrawn in 1967), but historically important and still occasionally asked.

Modified measles

Occurs when there is partial immunity to measles at the time of infection. Three typical settings:

• Infants 6–9 months with waning maternal antibody.
• Recipients of recent post-exposure NHIG.
• Previously vaccinated persons with breakthrough infection (secondary vaccine failure).

Features are attenuated compared with classic measles:

• Shorter incubation, milder prodrome.
• Rash less pronounced, often shorter and faster-fading.
• Koplik’s spots often absent.
• Lower viraemia; less severe illness; fewer complications.
• Serology may be ambiguous — IgM is positive but at a lower IgM:IgG ratio than in primary infection; avidity testing helps.
• Still transmissible — and an important driver of under-recognised onward transmission in vaccinated populations.